Patients With Chronic Pain Feel Caught In An Opioid Prescribing Debate

Patients With Chronic Pain Feel Caught In An Opioid Prescribing Debate

https://www.npr.org/sections/health-shots/2018/07/08/622729300/patients-with-chronic-pain-feel-caught-in-an-opioid-prescribing-debate

It started with a rolled ankle during a routine training exercise.

Shannon Hubbard never imagined it was the prologue to one of the most debilitating pain conditions known to exist, called ­­­­­­­complex regional pain syndrome.

It’s a condition that causes the nervous system to go haywire, creating pain disproportionate to the actual injury. It can also affect how the body regulates temperature and blood flow.

For Hubbard, it manifested several years ago following surgery on her foot. That’s a common way for it to take hold.

“My leg feels like it’s on fire pretty much all the time. It spreads to different parts of your body,” the 47-year-old Army veteran says.

Hubbard props up her leg, careful not to graze it against the kitchen table in her home east of Phoenix. It’s red and swollen, still scarred from an ulcer that landed her in the hospital a few months ago.

“That started as a little blister and four days later it was like the size of a baseball,” she says. “They had to cut it open and then it got infected and because I have blood flow issues, it doesn’t heal.”

She knows that soon it will happen again.

“Over the past three years, I’ve been prescribed over sixty different medications and combinations, none have even touched the pain,” she says.

She holds up a plastic bag filled with discarded pill bottles — evidence of her elusive search for a solution to the pain.

Hubbard says she’s had injections and even traveled across the country for infusions of ketamine, an anesthetic which can be used for pain in extreme cases. Her doctors have discussed amputating her leg because of the frequency of the infections.

“I’ve tried the other treatments. All I can do is manage the pain,” she says. “Opioids have become the best solution.”

For about nine months, Hubbard was on a combination of short- and long-acting opioids. She says it gave her enough relief to start leaving the house again and do physical therapy.

But in April that changed.

At her monthly appointment, her pain doctor informed her the dose was being lowered.

“They told me because of the new Arizona law they had to cut me back,” she says. “They had to take one of the pills away. That had a huge impact on my pain.”

Hubbard knew about those rules. They’re part of the state’s new opioid law, which places restrictions on prescribing and limits the maximum dose for most patients. She also knew the law wasn’t supposed to affect her — an existing patient with chronic pain.

Hubbard argued with the doctor, without success.

“They didn’t indicate there was any medical reason for cutting me back. It was simply because of the pressure of the opioid rules.”

Hubbard’s dose was lowered from 100 morphine milligram equivalents daily (MME) to 90, the highest dose allowed for many new patients in Arizona.

She says her pain has been “terrible” since they lowered her dose.

“It just hurts, I don’t want to walk, I don’t want to … pretty much don’t’ want to do anything,” she says.

Hubbard’s condition may be extreme, but her situation isn’t unique.

Faced with skyrocketing drug overdoses, states are cracking down on opioid prescribing. Increasingly, some patients with chronic pain like Hubbard say they are becoming collateral damage.

New limits on prescribing

More than two dozen states have implemented laws or policies limiting opioid prescriptions in some way. The most common is to restrict a patient’s first prescription to a number of pills that should last a week or less. But some states like Arizona have gone further by placing a ceiling on the maximum dose for most patients.

The Arizona Opioid Epidemic Act was passed earlier this year with unanimous support.

The law was the culmination of months of outreach and planning by state health officials.

It started in June of 2017, when Arizona’s Republican Governor Doug Ducey declared a public health emergency, citing new data, showing that two people were dying every day in the state from opioid overdoses.

He’s pledged to come after those responsible for the rising death toll.

“All bad actors will be held accountable — whether they are doctors, manufacturers or just plain drug dealers,” Ducey said in his annual State of the State address, in early January 2018.

The Governor went on to cite statistics from one rural county where four doctors prescribed six million pills in a single year, concluding “something has gone terribly, terribly wrong.”

Arizona Gov. Doug Ducey’s moves against opioid over-prescribing initially faced resistance from the state’s medical associations.

Will Stone/KJZZ

Later in January, Ducey called a special session of the Arizona legislature and in less than a week he signed the Arizona Opioid Epidemic Act into law. He called it the “most comprehensive and thoughtful package any state has passed to address this issue and crisis to date.”

The law expands access to addiction treatment, ramps up oversight of prescribing and protects drug users who call 911 to report an overdose from prosecution, among other things.

Initially, Arizona’s major medical associations cautioned against what they saw as too much interference in clinical practice, especially since opioid prescriptions were already on the decline.

Gov. Ducey’s administration offered assurances that the law would “maintain access for chronic pain sufferers and others who rely on these drugs.” Restrictions would apply only to new patients. Cancer, trauma, end-of-life and other serious cases were exempted. Ultimately, the medical establishment came out in favor of the law, which passed unanimously.

Pressure on doctors

Since the passage of the law, some doctors in Arizona report feeling pressure to lower patient doses, even for patients who have been on stable regimens of opioids for years without trouble.

Dr. Julian Grove knows the nuances of Arizona’s new law better than most physicians. A pain doctor, Grove worked with the state on the prescribing rules in the new law.

“We moved the needle to a degree so that many patients wouldn’t be as severely affected,” says Grove who’s also president of the Arizona Pain Society. “But I’ll be the first to say this has certainly caused a lot of patients problems, anxiety,” he says.

“Many people who are prescribing medications have moved to a much more conservative stance and unfortunately pain patients are being negatively affected.”

Like many states, Arizona has looked to its prescription monitoring program as a key tool for tracking overprescribing. State law requires prescribers to check the online database. Report cards are sent out comparing each prescriber to the rest of their cohort. Clinicians consider their scores when deciding how to manage patients’ care, Grove says.

“A lot of practitioners are reducing opioid medications, not from a clinical perspective, but more from a legal and regulatory perspective for fear of investigation,” Grove says. “No practitioner wants to be the highest prescriber.”

Julian Grove, MD, a pain specialist, says that doctors were already facing pressure on many fronts to reduce treatment by opioids in Arizona.

Will Stone/KJZZ

Arizona’s new prescribing rules don’t apply to board-certified pain specialists like Grove, who are trained to care for patients with complex chronic pain.

But, says Grove, the reality is that doctors — even pain specialists — were already facing pressure on many fronts to curtail opioids — from the Drug Enforcement Agency to health insurers down to state medical boards.

The new state law has only made the reduction of opioids “more fast and furious,” he says.

Grove traces the hypervigilance back to guidelines put out by the Centers for Disease Control and Prevention in 2016. The CDC spelled out the risks associated with higher doses of opioids and advised clinicians when starting a patient on opioids to prescribe the lowest effective dosage.

“They have been grossly misinterpreted,” says psychiatrist Sally Satel.

Satel, a fellow at the American Enterprise Institute, says those guidelines stipulated the decision to lower a patient’s dose should be decided on a case-by-case basis, not by means of a blanket policy.

The guidelines were not intended for pain specialists, but rather for primary care physicians, a group that accounted for nearly half of all opioids dispensed between 2007 and 2012.

“There is no mandate to reduce doses on people who have been doing well,” Satel says.

She says in the rush to address the nation’s opioid overdose crisis the CDC’s guidelines have become the model for many regulators and state legislatures.

“It’s a very, very unhealthy, deeply chilled environment in which doctors and patients who have chronic pain can no longer work together,” she says.

Satel calls the notion that new prescribing laws will reverse the tide of drug overdose deaths “misguided.”

“They are often looked to as a strategy that can make an enormous impact on the problem, and that is not true,” she says.

In fact, the rate of opioid prescribing nationally has declined in recent years, though it still soars above the levels of the 1990s. Meanwhile, more people are dying from illicit drugs like heroin and fentanyl than prescription opioids.

In Arizona, more than 1,300 people have died from opioid-related overdoses since June of last year, according to preliminary state numbers. Only a third of those deaths involved just a prescription painkiller.

Heroin is now almost as common as oxycodone in overdose cases in Arizona.

A range of views

Some physicians are supportive of the new rules, according to Pete Wertheim, executive director of the Arizona Osteopathic Medical Association.

“For some, it has been a welcome relief.” he says. “They feel like it has given them an avenue, a means to confront patients.” Some doctors tell him it’s an opportunity to have a tough conversation with patients who they believe are at risk for addiction or overdose because of the medication.

The organization is striving to educate its members about Arizona’s prescribing rules and the exemptions. But he says most doctors now feel like the message is clear: “we don’t want you prescribing opioids.”

Long before the law passed, Wertheim said physicians were already telling him that they had stopped prescribing, because they “didn’t want the liability.”

He worries the current climate around prescribing will drive doctors out of pain management, especially in rural areas.

There’s also a fear that the current climate will push some patients who can’t get prescription pills to try stronger street drugs, says Dr. Gerald Harris II, an addiction treatment specialist in Glendale, Ariz.

He says he’s seen an increase in referrals from doctors concerned that their patients with chronic pain are addicted to opioids.

Harris also receives new patients — almost daily, he says — whose doctors have stopped prescribing altogether.

“Their doctor is afraid and he’s cut them off,” he says. “Unfortunately, a great many patients turn to street heroin and other drugs to self-medicate because they couldn’t get the medications they need.”

Gerald Harris II, DO, specializes in treating addiction in Glendale, Az. He says he’s seen an increase in referrals from doctors concerned that their patients with chronic pain are addicted to opioids.

Will Stone/KJZZ

Arizona’s Department of Health Services is working to reassure providers and dispel the myths, according to Dr. Cara Christ, who heads the agency and helped design the state’s opioid response. She points to the recently launched Opioid Assistance and Referral Line created to help health care providers with complex cases. The state has also released a set of detailed prescribing guidelines for doctors.

Christ characterizes this as an “adjustment period” while doctors learn the new rules.

“The intent was never to stop prescribers from utilizing opioids,” she says. “It’s really meant to prevent a future generation from developing opioid use disorder, while not impacting current chronic pain patients.”

Christ says she just hasn’t heard of many patients losing access to medicine.

It’s still too early to gauge the law’s success, she says, but opioid prescriptions continue to go down in Arizona.

Arizona saw a 33 percent reduction in the number of opioid prescriptions in April, as compared to the same period last year, according to state data. Christ’s agency reports more people are also getting help for addiction. There has been about a 40 percent increase in hospitals referring patients for behavioral health treatment following an overdose.

Shannon Hubbard, the woman living complex regional pain syndrome, considers herself fortunate that her doctors didn’t cut back her painkiller dose even more.

“I’m actually kind of lucky that I have such a severe case because at least they can’t say I’m crazy or it’s in my head,” she says.

Hubbard is well aware that people are dying everyday from opioids. One of her family members struggles with heroin addiction and she’s helping raise his daughter. But she’s adamant that there’s a better way to address the crisis.

“What they are doing is not working. They are having no effect on the guy who is on the street shooting heroin and is really in danger of overdosing.” she says.

“Instead they are hurting people that are actually helped by the drugs.”

FDA joins 22 countries’ recall of common heart drug

FDA joins 22 countries’ recall of common heart drug

https://www.cnn.com/2018/07/13/health/valsartan-recall-fda-bn/index.html

(CNN)A common drug used to control blood pressure and help prevent heart failure was announced by the US Food and Drug Administration on Friday, a week after 22 other countries recalled it because the drug contains a chemical that poses a potential cancer risk.

Valsartan is off patent and is used as a component of other generic medicines, but not all medicines containing the ingredient are involved, according to the FDA. The US recall includes the the versions of valsartan that are made by Major Pharmaceuticals, Solco Healthcare and Teva Pharmaceuticals Industries Ltd. as well as valsartan/hydrochlorothiazide (HCTZ) sold by Solco Healthcare and Teva Pharmaceuticals Industries Ltd.
“We have carefully assessed the valsartan-containing medications sold in the United States, and we’ve found that the valsartan sold by these specific companies does not meet our safety standards. This is why we’ve asked these companies to take immediate action to protect patients,” said Dr. Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research.
In Europe and Asia, Novartis, the company that originally developed the drug, said Sandoz valsartan and valsartan/HCT film-coated tablets are being recalled because they “do not meet our high quality standards.” Pharmacies in the UK are advised to recall valsartan batches containing medicines made by Dexcel Pharma Ltd and Accord Healthcare.
The recall is due to the presence of the impurity, N-nitrosodimethylamine (NDMA), which was found in the recalled products, according to an FDA statement.
NDMA is an organic chemical that is in a family of potent carcinogens. It has been used to make liquid rocket fuel, softeners and lubricants, among other products. It can also be unintentionally produced through certain chemical reactions and is a byproduct from some pesticide manufacturing, the making of rubber tires or fish processing.
Animal studies have shown that NDMA can be toxic and cause tumors in the liver, kidney and respiratory tract. It can also be potentially harmful to humans in certain quantities. Exposure to high levels can cause liver damage and is a probable human carcinogen, according to the US Department of Health and Human Services.
Novartis spokesman Eric Althoff said after the initial recall last week that products sold in the US were not affected by this recall, but the FDA’s ongoing review and laboratory tests found otherwise. “The presence of of NDMA was unexpected and is thought to be related to changes in the way the active substance was manufactured,” the FDA release said.
“The amounts of NDMA found in Valsartan API are much lower than the cumulative endogenous production and usual external exposure of NDMA,” Althoff wrote in an email July 6. “There is no certainty as to how much this contaminant may potentially increase cancer risk in humans. Thus, the amount of NDMA found in the Valsartan API would not represent a significantly increased risk to the patients taking of Sandoz Valsartan and Sandoz Valsartan HCT Film coated tablets.”
The FDA’s investigation into the drug will continue.
Follow CNN Health on Facebook and Twitter

See the latest news and share your comments with CNN Health on Facebook and Twitter.

“The FDA is committed to maintaining our gold standard for safety and efficacy. That includes our efforts to ensure the quality of drugs and the safe manner in which they’re manufactured,” Commissioner Dr. Scott Gottlieb said Friday. “When we identify lapses in the quality of drugs and problems with their manufacturing that have the potential to create risks to patients, we’re committed to taking swift action to alert the public and help facilitate the removal of the products from the market. As we seek the removal of certain drug products today, our drug shortages team is also working hard to ensure patients’ therapeutic needs are met in the United States with an adequate supply of unaffected medications.”
Patients are advised to talk to their doctor if they are taking the medication. They should not discontinue taking medication without a doctor’s permission. Going off their medication without supervision could be dangerous, according to the American Heart Association.

NV: opiate dosing guidelines — what could go wrong ?

 

 

 

Woman shoots herself in back to alleviate pain

ROBINSON, TX (KXXV) –

A woman was taken to the hospital Friday morning after a shooting in Robinson. 

Robinson police were on the scene in the 600 block of Karnes Drive in Robinson. Police said that a 76-year-old woman had shot herself in the back after experiencing chronic pain that she could no longer tolerate. 

The woman was found in the driveway with a gunshot wound to the right hip. She told officers that she hoped that now she could experience relief from the back pain. 

A intractable chronic pain pt can be “created” in a “heartbeat’

interesting read

accountability-torture-health-20110511

Whistleblower”: Former employees take on pediatric dental chain when they suspect the company of wrongdoing

Kool SmilesProduction Metrics are EVERYWHERE- healthcare is just a FOR PROFIT BUSINESS

Whistleblower”: Former employees take on pediatric dental chain when they suspect the company of wrongdoing

New synthetic opioids are killing even more people, CDC says

New synthetic opioids are killing even more people, CDC says

http://www.wrcbtv.com/story/38638014/new-synthetic-opioids-are-killing-even-more-people-cdc-says

New synthetic opioids are killing more people than ever before, with more than half of all opioid overdose deaths caused by the powerful, lab-made drugs, federal officials said Wednesday.

The Centers for Disease Control and Prevention issued a Health Alert Network warning about the increased supply of the illicit drugs, which are many times stronger than fentanyl, the prescription painkiller.

“The dramatic rise in the supply of illicitly manufactured fentanyl and fentanyl analogs has been mirrored by an equally dramatic rise in deaths involving synthetic opioids other than methadone, a category which includes fentanyl and fentanyl analogs,” the CDC said in its alert.

Death rates doubled between 2015 and 2016, the CDC said. “More than 55 percent of opioid overdose deaths occurring nationally in the 12 months ending November 2017 involved synthetic opioids, accounting for more than 27,000 overdose deaths,” the CDC said in the health alert, citing preliminary numbers.

That’s up from 20,000 overdose deaths from synthetic opioids in 2016.

People who overdose on the synthetics may need multiple doses of naloxone, the drug that can reverse an overdose, the CDC added.

The new drugs include carfentanil, which is 100 times more potent than fentanyl, the CDC said. Another is 3-methylfentanyl, which is four times as powerful. Deaths from these drugs nearly doubled from 2016 to 2017, the CDC said.

Other illicit synthetic opioids include furanylfentanyl and acrylfentanyl. “Finally, drug submissions testing positive for a synthetic illicit opioid known as U-47700, first encountered by the DEA in 2016, increased from 533 submissions in 2016 to 1,087 during January–June, 2017,” the CDC said in the alert, referring to the Drug Enforcement Administration.

Some of the new drugs may not be detected by standard tests, and coroners and medical examiners may need to use a mass spectrometer to detect the substances.

And they’re often being used to cut other drugs, such as cocaine, the CDC said.

The U.S. is suffering through a terrible epidemic of opioid abuse. Opioids, including prescription opioids and heroin, killed 42,000 people in 2016, the CDC says. Opioid overdose deaths are so bad that they have helped drive down U.S. life expectancy.

Starting in 2016, most deaths were caused by the street synthetics. That continued into 2017, the CDC said. “This 12-month sum of synthetic opioid overdose deaths exceeds the total number of all opioid overdose deaths in 2013, when deaths involving synthetic opioids first began to climb,” the CDC said.

“Ohio alone reported more than 1,700 opioid overdose deaths testing positive for fentanyl analogs during July 2016–June 2017, with more than 1,100 of those deaths involving carfentanil.”

Emergency responders and physicians may not know that people overdosing on the synthetics may need extra care, the CDC said.

“Orally ingested counterfeit pills laced with fentanyl or fentanyl analogs may require prolonged dosing of naloxone in the ED hospital setting due to a delayed toxicity that has been reported in some cases,” the CDC said.

Medical Marijuana Reduces Opioid Prescriptions, Another Study Finds

https://www.forbes.com/sites/tomangell/2018/07/11/medical-marijuana-reduces-opioid-prescriptions-another-study-finds/#5aece6186b00

The latest in a string of studies to demonstrate a link between medical marijuana legalization and lower opioid use rates has just been released.

Photo by Tom SydowPhoto by Tom Sydow

“In this study, we found that statewide medical cannabis legalization implemented in 1993 – 2014 in the US was associated with close to 30% reductions in Schedule III opioids received by Medicaid enrollees,” the researchers, from the University of California San Diego and Weill Cornell Medical College, wrote in the journal Addiction.

Calculating the cost of opioid pain drugs that patients would have otherwise purchased, the study estimated that medical cannabis legalization in states that have so far adopted it saves the federal government $7.46 million in annual Medicaid spending. Add to that an additional $6.54 million in savings for states.

“[I]f all the states had legalized medical cannabis by 2014, Medicaid annual spending on opioid prescriptions would be reduced by 17.8 million dollars,” the study projected.

While the research showed a clear reduction in prescriptions of Schedule III opioids, it did not find a correlation between allowance of medical marijuana and use of drugs classified under the more restrictive Schedule II of the Controlled Substances Act.

“[E]vidence suggested that cannabis provides mild to moderate relief from pain, on par with Codeine, making cannabis a better alternative to Schedule III opioids,” the researchers wrote in the study, published this week. “Although there is emerging evidence suggesting that cannabis is effective in treating severe pain, no studies compared the analgesic efficacy of the cannabinoids with Schedule II opioids. Due to the concern of cannabis’ lack of efficacy on severe pain symptoms, patients prescribed Schedule II opioids might be less likely to switch to medical cannabis and physicians might be less likely to recommend medical cannabis to these patients.”

The new results expand on findings of other studies released earlier this year which found that “medical cannabis laws are associated with significant reductions in opioid prescribing in the Medicare Part D population” and that state marijuana policies “have the potential to lower opioid prescribing for Medicaid enrollees.”

Sen McCaskill running for reelection in a “Trump state” and pulling out all statistical LIES ?

System for reporting suspicious opioid orders repeatedly failed, report finds

www.statnews.com/2018/07/12/senate-report-opioids-distribution/

WASHINGTON — A Senate report released Thursday lays out systematic failures in the reporting system for suspicious opioid orders, faulting some drug distributors and manufacturers for their roles and criticizing the Drug Enforcement Administration for a years-long lull in enforcement actions.

The findings, the latest in a series of reports from Sen. Claire McCaskill (D-Mo.), the top Democrat on the Senate’s leading oversight committee, pointed in particular to disparities between two leading drug distributors: McKesson and AmerisourceBergen.

The two distributors shipped nearly identical volumes of opioids to Missouri between 2012 and 2017: roughly 650 million doses each.

But the number of orders each company flagged to authorities as suspicious were nowhere close: 224 from AmerisourceBergen and 16,714 from McKesson.

Taken together, the “Big Three” group of distributors, including Cardinal Health, sent 52 dosage units for each of the state’s citizens in 2015.

“It’s staggering. Over six years we averaged 260 pills for every man, woman, and child in Missouri,” McCaskill said in a statement. “The opioid crisis these pills have fueled is a failure of policy and oversight by the government and a failure of basic human morality on the part of many pharmaceutical companies and distributors — a failure that has destroyed families and communities all over our state.”

Suspicious painkiller shipments have been a focus for lawmakers working to stem the opioid crisis, ranging from a contentious House hearing to McCaskill’s ongoing investigations and even surfacing Wednesday at a confirmation hearing for Jim Carroll, President Trump’s nominee as “drug czar.”

McCaskill’s latest report found that “certain major distributors and manufacturers have consistently failed to meet their anti-diversion obligations.”

While the report did not directly allege violations of the Controlled Substances Act, it also highlighted differences between how pharmaceutical companies that manufacture opioids worked with the DEA. Endo Pharmaceuticals flagged hundreds of orders and conducted further internal reviews but concluded none was suspicious enough to report to the DEA; Mallinckrodt Pharmaceuticals, meanwhile, reported every order it flagged regardless of what its internal review found.

Nonetheless, McCaskill’s report said, the DEA had estimated that Mallinckrodt “failed to report at least 43,991 opioid orders.”

Citing a previous $35 million settlement reached with Mallinckrodt, the report also noted the Justice Department’s finding that the company had “failed to design and implement an effective system to detect and report ‘suspicious orders’ for controlled substances.” McKesson agreed to pay a $150 million settlement after the Justice Department reached the same conclusion about its distribution procedures.

A spokesman said Mallinckrodt had disagreed with the allegations yet chose to settle “to eliminate the uncertainty, distraction, and expense of litigation” and that the company had worked diligently with McCaskill’s office and the DEA. 

“The report acknowledges Mallinckrodt takes a robust (or as the report states ‘conservative’) approach to its suspicious order monitoring obligations, and in the period covered by the report provided nearly 1,000 suspicious order reports to the U.S. DEA while other manufacturers reported none,” the spokesman said. 

Much of the conversation on Capitol Hill regarding opioids has centered on particularly egregious examples of opioid oversupply — which lawmakers have blamed on drug manufacturers, distributors, pharmacies, doctors, and the DEA itself.

The Justice Department, which oversees the DEA, on Wednesday sought to curb that supply, releasing the final version of a rule that would allow it to factor predicted drug diversion into the formula it uses to award “quota” to manufacturers, a proposal that drew skepticism when first announced in April.  

Polling has consistently shown Americans believe the opioid crisis should be a high priority for the federal government. McCaskill, who is running in a competitive re-election race in her home state, has made oversight of companies that manufacture and distribute painkillers a priority this Congress. And while most of her work has focused on the problem nationally, much of Thursday’s report was specific to Missouri.

But the report also singled out Teva Pharmaceuticals, among the world’s largest drug manufacturers, for not complying with McCaskill’s document requests. Sen. Ron Johnson (R-Wis.), who chairs the Senate Homeland Security and Governmental Affairs Committee, denied McCaskill’s request to subpoena the company in January, and told STAT in May that he believed holding opioid manufacturers and distributors accountable for their actions was largely a job for the courts, not Congress.  

“The two overlapping trends described in this report — disparities in industry compliance behavior and declining DEA enforcement — suggest, at the very least, a connection between weak DEA oversight and varying anti-diversion efforts,” the report read.

In an email, a spokeswoman for AmerisourceBergen pointed to the company’s detailed daily reports to the DEA, and stressed that the DEA has not provided guidance as to whether it prefers human-reviewed or algorithm-based reporting.

“Regarding the variation in the number of suspicious orders reported, AmerisourceBergen’s order monitoring program involves two key steps,” the spokeswoman wrote. “Flagging orders for review using our complex computer algorithm and conducting a detailed investigation of every single flagged order. We believe this process makes our suspicious order reports to the DEA highly precise and actionable.”

A McKesson spokeswoman declined to comment on the report Wednesday, prior to its release, but said the company had invested heavily in its anti-diversion program and advocated for policy changes it felt would help address overprescribing. Representatives for Teva and Endo did not immediately respond to requests for comment.

Whoever wrote this article and pull “the numbers” for her…  The article states 650,000 doses from two drug wholesalers from 2012 to 2017 – as I count that… that is SIX YEARS. That is 1.3 billion doses.. there is an estimated 6 million population in MO…

If you use best practices and standard of care to treat the estimated 600,000 intractable chronic pain… that would be 2-3 long acting and up to 4 doses of shot acting meds.. that would be abt 210 doses/month, 1.5 billion doses/yr just to treat the intractable chronic pain pts..  that leaves nothing for the 420,000 chronic pain pts that have a “as needed doses of opiates”, NOTHING for people who have surgical procedures, accidents and whatever other causes of acute pain.

So while it would appear that Sen McCaskill’s presentation of “the numbers” seems to strongly suggest that she has proven that the vast majority of pts that have need for pain management are being GROSSLY UNDER TREATED.

Sen McCaskill has served TWO – SIX year terms in the Senate..maybe it is time for term limits for her. She obviously has signed on to the idea that opiates are the stepping stones to addiction.